Daiichi Wins Lawsuit Against Mylan Pharmaceuticals Regarding Patents for Levofloxacin.Tokyo, Japan, Dec 27, 2005 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Daiichi Sankyo has announced that its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. Daiichi Pharmaceutical has won the lawsuit against Mylan Pharmaceuticals. Specifically, the US Court of Appeals for the Federal Circuit has affirmed af·firm v. af·firmed, af·firm·ing, af·firms v.tr. 1. To declare positively or firmly; maintain to be true. 2. To support or uphold the validity of; confirm. v.intr. the validity of US patent (No. 5,053,407) on levofloxacin, a broad spectrum synthetic antibacterial antibacterial /an·ti·bac·te·ri·al/ (-bak-ter´e-al) destroying or suppressing growth or reproduction of bacteria; also, an agent that does this. an·ti·bac·te·ri·al adj. agent held by Daiichi. Consequently, Mylain is prohibited from producing any generic version of levofloxacin until Daiichi's patent expires. Currently, levofloxacin is marketed under the trade names of Cravit in Japan and Levaquin in the US. Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion